The Syner-KINASE® solution: thrombolytic therapy for catheter occlusions

The Syner-KINASE® solution: thrombolytic therapy for catheter occlusions

Access to a reliable and efficient thrombolytic agent is essential in settings where a blocked catheter can cause significant treatment delays. Syner-KINASE (urokinase) can provide a versatile and clinically proven solution that can help to restore catheter function quickly, supporting seamless patient care.

Step-by-step mechanism of action of Syner-KINASE: fibrin forms a clot, Syner-KINASE binds to plasminogen converting it into plasmin, which then targets and breaks down fibrin to clear the clot.

How Syner-KINASE works as a plasminogen activator

How Syner-KINASE works as a plasminogen activator

Syner-KINASE converts plasminogen – a protein abundant in the thrombus – into plasmin, an enzyme that breaks down the fibrin structural component of blood clots. By targeting the fibrin network directly, this thrombolytic solution aids rapid clot dissolution and efficient catheter clearance.

Contraindications, warnings and adverse effects

As a thrombolytic, Syner-KINASE is contraindicated in patients at serious risk from bleeding. It should be used with caution in patients where the risk may be increased, and its use should be weighed against the anticipated benefits of treatment.
See the full Summary of Product Characteristics (SmPC) here: https://www.medicines.org.uk/emc/product/7565

Contraindications
• Hypersensitivity to the active substance or excipients
• Active, clinically relevant bleeding
• Recent severe gastrointestinal bleeding, major surgery, cerebrovascular accident or trauma, or obstetric delivery
• Severe hypertension or severe hepatic/renal insufficiency (unless on renal replacement therapy)
• Coagulation defects and severe thrombocytopenia
• Aneurysm or arteriovenous malformation
• Intracranial neoplasm or other neoplasm with risk of haemorrhage
• Acute pancreatitis, pericarditis, bacterial endocarditis or sepsis

Warnings and precautions
• Conditions where there is an increased risk of bleeding
• Bleeding from sites of percutaneous trauma
• Haematoma formation
• Avoid arterial invasive procedures if possible
• If bleeding occurs during treatment, Syner-KINASE should be stopped immediately

Adverse effects

Very common:
• Haemorrhage, including from puncture or wound site
• Decrease in haematocrit without clinically detectable bleeding
• Transient increase in transaminases

Common:
• Fever, chills
• Gastrointestinal, intracranial, retroperitoneal, urogenital and muscle haemorrhage
• Stroke

Uncommon:
• Intrahepatic haemorrhage
• Renal failure

Rare:
• Hypersensitivity reactions (urticaria, dyspnoea, hypotension, flushing, rash)
• Vascular pseudoaneurysm
• Macroscopic haematuria

Very rare:
• Anaphylaxis

Close-up of healthcare professional administering intravenous catheter for thrombolytic drug delivery in a clinical setting

Dual administration advantage: urokinase lock and infusion

Syner-Kinase is the only thrombolytic licensed in the UK for catheter clearance using both locks and infusions.

Catheter lock

  1. Lock: Direct instillation into the catheter lumen to clear intraluminal thrombi
  2. Infusion: Systemic administration for broader clot resolution inside or outside of the catheter

This dual approach allows healthcare providers to tailor treatment based on the specific nature of the catheter occlusion and patient characteristics.

Healthcare professionals monitoring elderly patients in a hospital ward with advanced medical beds

A quick and efficient solution

Time-sensitive treatments, such as haemodialysis and chemotherapy, require fast-acting solutions. Syner-KINASE’s 30-60 minute lock protocol helps to minimise treatment disruptions and maximise patient throughput, supporting continuous and effective care.

Syner-Kinase® Human Urokinase vials and packaging in 10,000, 25,000, and 100,000 IU doses

Customisable dosing for varied clinical needs

Different patients and clinical scenarios require different interventions. Syner-KINASE offers a range of flexible dosing options. The availability of multiple dose strengths – 10,000, 25,000, 100,000 and 250,000 IU – can provide efficacy with minimal waste, enabling precise and patient-specific treatments.

Gloved hand opening laboratory refrigerator containing temperature-sensitive medical vials

Overcoming logistical challenges with room temperature storage

Some thrombolytic agents require cold chain storage, but Syner-KINASE is supplied as a lyophilised powder that can be stored at room temperature and easily reconstituted. This can simplify inventory management and make treatment more accessible for hospitals, dialysis centres and outpatient settings.

Discover more about Syner-KINASE

Discover more about Syner-KINASE

Medical stent partially blocked by arterial plaque buildup with fibrous tissue

Learn about catheter thrombosis and why thrombolytic therapy is essential

Syner-Kinase® Human Urokinase vials and packaging in 10,000, 25,000, and 100,000 IU doses

Find out more about
Syner-KINASE®

Audience attending a medical conference, with expert speakers on stage discussing innovations in thrombolytic therapy and cardiovascular care.

Watch expert-led discussions on thrombolysis for catheter blockages

Have questions or need more information?

Have questions or need more information?

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. 

Adverse events should also be reported to Syner-Med (PP) Ltd. Tel: +44 (0)208 655 6380

For Syner-KINASE prescribing information, click here